Objective: The most promising bone pain palliative agent such as 177Lu-EDTMP emerges as a newer radiopharmaceutical
for cancer management. Thus, it was of interest to study the cell uptake of this agent in osteocarcinoma cell line and investigate
the underlying mechanism of cellular toxicity.
Methods: The cell binding studies of 177Lu-EDTMP were carried out in osteocarcinoma cells (MG63) after induction of
bone mineralization. Cellular toxicity studies were carried out with varying amounts of 177Lu-EDTMP and compared with
equivalent amount of cold Lu-EDTMP. Cell viability was assessed by trypan blue, LDH and MTT assay. Different studies
such as DNA fragmentation and Western blotting for apoptosis related proteins were carried out to elucidate the mechanism
of cell death.
Results: Maximum cell binding of 177Lu-EDTMP, observed with mineralized MG63 cells was 19 ± 0.122 %. Nearly 12%
cell death was observed in MG63 cells treated with 37 MBq of 177Lu-EDTMP as compared to controls. Apoptosis studies
were carried out by ELISA to estimate DNA fragmentation and it was found that DNA enrichment factor was 1.8, compared
to the corresponding control. Down regulation of anti-apoptotic protein, bcl-2 and cleavage of PARP protein was
evident by Western blot results.
Conclusion: These studies indicate that the 177Lu-EDTMP binds to mineralized bone cells and induces apoptotic cell
death in MG63 cells.